Clinical Trial Risk: The failure of ongoing or future clinical trials for Karyopharm's drug candidates, including new indications for XPOVIO or pipeline assets, could significantly impact the company's prospects and valuation.

Regulatory Approval Risk: Karyopharm faces the risk of not obtaining or maintaining necessary regulatory approvals from health authorities like the FDA and EMA for its current or future drug products, which could delay or prevent market access.

Commercialization and Market Adoption Risk: Despite regulatory approvals, Karyopharm may struggle to achieve widespread market adoption and sales growth for XPOVIO or any future products due to factors such as physician prescribing habits, payer reimbursement policies, or market awareness.